Charles M. Baum, MD, PhD



Dr. Baum was appointed President and Chief Executive Officer and Board Member of Mirati Therapeutics in November 2012. Since then, he has been responsible for moving the company to the United States, listing the company on NASDAQ and establishing its headquarters in San Diego, California. In addition, he has built a world class precision oncology leadership team and transformed Mirati into a company focused on the innovative, targeted development of Mirati’s receptor tyrosine kinase and histone deacetylase inhibitors in various cancers.

Prior to joining Mirati he was Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division. Dr. Baum was at Pfizer from 2003 until joining Mirati in 2012, serving in roles of increasing responsibility including as Vice President and Head of Oncology Development and as Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. He was responsible for the development of the oncology portfolio, including Axitinib (Inlyta®), Crizotinib (Xalkori®) and the approval of sunitinib (Sutent®) for the treatment of gastrointestinal stromal tumor (GIST) and renal cell carcinoma. Prior to joining Pfizer, Dr. Baum was responsible for the Phase I-IV development of several oncology compounds at Schering-Plough, including temozolomide (Temodar®) which was approved for the treatment of patients with advanced brain tumors.

His career has included academic and hospital positions at Stanford and Emory universities, as well as positions of increasing responsibility within the pharmaceutical industry (Systemix, Searle, Schering-Plough and Pfizer). Dr. Baum currently serves on the board of directors of Array BioPharma. Dr. Baum received his M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine in St. Louis, Missouri and completed his post-graduate training at Stanford University, California. Dr. Baum has received research support from the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts, and holds a number of patents and patent applications.

Isan Chen, MD



Isan Chen, MD is board certified in internal medicine, hematology and medical oncology with more than 15 years of experience in oncology and clinical trials from first-in-humans through global studies designed to support regulatory registration. He has experience in oncology clinical development and interactions with regulatory agencies in the US and Europe. He was most recently the Chief Medical Officer of Aragon Pharmaceuticals which was acquired by Johnson & Johnson in July of 2013. At Aragon, Dr. Chen was responsible for the clinical development strategy of all the company’s programs, including prostate and breast cancer. Prior to Aragon, Dr. Chen served as Vice President of Tumor Strategy in the oncology business unit at Pfizer. In addition he was the clinical lead for sunitinib (Sutent®), a multiple kinase inhibitor, for the treatment of renal cell carcinoma, an indication in which the drug secured FDA approval in 2006. He was also the clinical lead for the Phase I studies of crizotinib (Xalkori®) and CDK 4/6 inhibitor palbociclib.

Dr. Chen completed his hematology/oncology fellowship at University of California, San Diego. Before joining Pfizer, Dr. Chen practiced medicine as a staff physician at City of Hope Medical Center and later as an assistant professor at the University of Texas, M.D. Anderson Cancer Center.

Chris LeMasters


rob_2589-cropped1Mr. LeMasters joined Mirati in October 2016. Prior to joining Mirati, Mr. LeMasters served as the CEO of Promosome, a privately held biotherapeutics and synthetic biology company. Previously, Mr. LeMasters held senior management positions at several biotherapeutics companies, most recently as co-founder and chief business officer of Tragara Pharmaceuticals, a clinical-stage cancer therapeutics company. Mr. LeMasters also served as co-founder and chief business officer of Cabrellis Pharmaceuticals, Inc., where he negotiated its acquisition by Pharmion Corporation for $104 million, and as vice president, corporate development of Conforma Therapeutics, where he negotiated its acquisition by Biogen IDEC for $250 million. Mr. LeMasters also worked in the corporate business development group at Eli Lilly & Company and was responsible for the successful negotiation of numerous partnerships and licenses across a range of therapeutic areas. Earlier in his career, he was a management consultant with Coopers & Lybrand Consulting and an operational auditor with Owens Corning.

Mr. LeMasters currently serves as a board member of Aarden Pharmaceuticals, where he is also a co-founder, and as a board member of the Hoosier Cancer Research Network, a clinical research organization. He received a B.S. degree in Finance from Indiana University and an MBA with honors from the University of Chicago.

James Christensen, PhD



Dr. Christensen joined Mirati in June 2013. He was most recently the Senior Director of Oncology Precision Medicine in the Oncology Research Unit at Pfizer, a group focused on developing strategies toward patient identification, novel combination approaches, and development of biomarker approaches. Dr. Christensen joined Pfizer in 2003 and his responsibilities there included leading nonclinical research efforts for oncology programs including sunitinib (Sutent®) research activities and leading the nonclinical and translational biology efforts for other research and development programs including crizotinib (Xalkori®). Dr. Christensen participated as a member of the Pfizer Cancer Research or Oncology Research Unit leadership team from 2005-2013. Prior to 2003, Dr. Christensen was at SUGEN/Pharmacia as a Group Leader on the Preclinical Research and Exploratory Development team where he was responsible for leadership of c-Met and erbB family preclinical development programs and aspects of research and development for sunitinib. Dr. Christensen initiated his industry experience at Warner Lambert/Parke-Davis with research focus in receptor tyrosine kinase (RTK) biology and RTK pathway biomarker development in the oncology therapeutic area. Dr. Christensen has authored or co-authored over 100 peer-reviewed research articles in scientific journals including Science, Nature, Cancer Cell, New England Journal of Medicine and others. In addition, Dr. Christensen participates on the editorial boards for Cancer Research and Molecular Cancer Therapeutics.

Dr. Christensen received his PhD degree focusing in Molecular Pharmacology from North Carolina State University with dissertation research directed toward characterization of mechanisms of apoptosis dysregulation during the process of carcinogenesis.

Jamie Donadio



Mr. Donadio joined Mirati in March 2013. From April 2001 to January 2013, Mr. Donadio held a number of corporate finance and accounting positions at Amylin Pharmaceuticals, Inc., most recently serving as Senior Director of Finance with responsibility for corporate finance activities including financial planning and analysis, treasury and capital formation strategy.

Previously at Amylin, Mr. Donadio was responsible for the company’s SEC reporting and has extensive working knowledge of public company accounting and reporting matters. From December 2000 to April 2001 Mr. Donadio was Senior Accountant at Novatel Wireless, Inc. From August 1997 to December 2000 Mr. Donadio was with Ernst & Young LLP, last serving as an audit senior.

Mr. Donadio holds a B.S. in accounting from Babson College and is a certified public account (inactive) in the State of California.

Claire S. Padgett, Ph.D.


Dr. Claire Padgett joined Mirati in January 2017 as Senior Vice President, Clinical Operations. Dr. Padgett has more than 30 years of experience in global clinical research planning and execution supporting strategic development and operational management at biotechnology and pharmaceutical companies and contract research organizations. Before joining Mirati, she served as Vice President, Clinical Operations for Mast Therapeutics, Inc., Oncolytics Biotech, Inc., and Cylene Pharmaceuticals. Her previous experience includes oversight of clinical project management of Phase 1 through Phase 3 multinational trials over a broad range of therapeutic areas including oncology, hematology, neurological disease, endocrinology, gastrointestinal and pulmonary disorders, and cardiovascular disease. In her early career, Dr. Padgett served in various leadership positions of increasing responsibility in Conforma Therapeutics, which was acquired by Biogen-IDEC, Ligand Pharmaceuticals, Inc., Parexel International Corp., IBRD, subsequently acquired by INC Research, and Roche.

Dr. Padgett holds a Ph.D. in Organizational Management and Leadership from Capella University,
a M. S. in Biology and Business from Seton Hall University, and is a registered Medical Technologist (ASCP).

Perry C. Johnston



Mr. Johnston joined Mirati as an employee in February 2014 having previously supported the company in a consulting capacity commencing in July 2013. With more than twenty years of in-house experience, Mr. Johnston has served on senior leadership teams and helped build and lead legal, compliance, regulatory and risk management functions. From August 2009 to July 2013, Mr. Johnston served as Senior Director of Legal at Amylin Pharmaceuticalas, Inc. where he led the Transactions/Contracts Group and managed legal support for the Corporate Development, Business Development, and Alliance Management functions. Prior to joining Amylin, Mr. Johnston served in senior leadership roles with various biotechnology, health provider, and medical device companies, including as Vice President, General Counsel and Company Secretary at Advanced BioEnergy LLC, Vice President of Legal, Regulatory and Compliance at Aperio Technologies, Inc., Vice President, General Counsel and Corporate Secretary at the Nevada Cancer Institute, Vice President of Legal and Compliance at CardioNet, Inc., and Senior Legal Counsel at Medtronic, Inc. Mr. Johnston worked as an attorney in private practice for several years and began his career after law school in the tax field, working with both Coopers & Lybrand in Minneapolis and KPMG Peat Marwick in San Diego.

Mr. Johnston received his Juris Doctor degree from the University of Minnesota Law School and his B.S. Business Administration (finance and economics emphasis) from the University of Minnesota School of Management.

Vickie Reed


Ms. Reed joined Mirati in October 2013 and was named Vice President of Finance in December 2016. Previously, she served as Senior Director of Finance and Controller at Zogenix, Inc., a biotechnology company in Emeryville, California. From September 2009 to November 2012 Ms. Reed held corporate accounting positions at Amylin Pharmaceuticals, Inc., most recently serving as Director SEC Reporting and Revenue Accounting. Prior to joining Amylin, Ms. Reed held financial roles at several biotechnology and telecommunications companies.

Ms. Reed began her career with Price Waterhouse, now PricewaterhouseCoopers, in Denver, Colorado. Ms. Reed is a Certified Public Accountant in the State of Colorado, and received a B.S. in Accounting from University of Colorado Denver.

Sanjeev Sharma, Ph.D.



Sanjeev Sharma, Ph.D. joined Mirati as Senior Vice President of CMC and Product Development in July 2017. He has 25 years of experience in product development in the pharmaceutical industry, particularly process chemistry, formulation development, analytical sciences, and manufacturing, particularly process chemistry, formulation development, analytical sciences and manufacturing. He has been part of 5 approved NDAs and 3 commercial launches. He joined Mirati from NantKwest Inc. where he was the Vice President of Product Development and oversaw CMC development of a broad spectrum of drug delivery technologies including cell therapy, biologics and small molecules. Prior to NantKwest, Dr. Sharma held positions of increasing responsibility at various large, medium and small Pharma companies including, Pfizer, AbbVie, Exelixis, Arena and Onyx (acquired by Amgen).

Dr. Sharma holds a Ph.D. in Chemical Engineering from the University of Bradford, UK and completed post-doctoral research at the University of Illinois, Urbana.

Bydureon® is a registered trademark of Amylin Pharmaceuticals, Inc.
Temodar® is a registered trademark of Merck & Co., Inc.
Xalkori®, Inlyta® and Sutent® are registered trademarks of Pfizer, Inc.